Sign In
Buy MGNX
$3.69
-0.0900 (-2.38%)
At Close: Jul 31, 2026
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
10:35am, Monday, 27'th Jul 2026
MacroGenics is affirmed as a 'Buy' due to a de-risked operational runway and promising B7-H3 ADC pipeline asset. MGNX's pipeline is refocused after setbacks; cash infusions and divestitures extend the
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
04:01pm, Thursday, 23'rd Jul 2026
Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026 Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enro
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
01:01pm, Thursday, 02'nd Jul 2026
Does MacroGenics (MGNX) have what it takes to be a top stock pick for momentum investors? Let's find out.
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
09:25am, Thursday, 02'nd Jul 2026
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the trea
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
04:43pm, Monday, 22'nd Jun 2026
ROCKVILLE, MD, June 22, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
04:01pm, Thursday, 14'th May 2026
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
06:36pm, Wednesday, 13'th May 2026
MacroGenics (MGNX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to a loss of $0.65 per share a year ago.
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
04:01pm, Wednesday, 13'th May 2026
ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
05:20pm, Monday, 11'th May 2026
•MacroGenics to receive $122. 5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora ROCKVILLE, MD,
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
05:20pm, Monday, 11'th May 2026
•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora
Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know
11:00am, Tuesday, 05'th May 2026
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
07:30am, Monday, 04'th May 2026
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million • MacroGe
FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study
04:30pm, Wednesday, 08'th Apr 2026
• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenic
MacroGenics (NASDAQ:MGNX) & Medtronic (NYSE:MDT) Critical Review
01:09am, Monday, 06'th Apr 2026
Medtronic (NYSE: MDT - Get Free Report) and MacroGenics (NASDAQ: MGNX - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the
MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
01:12pm, Thursday, 12'th Mar 2026
MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
